The Mitochondrial ATP-Sensitive Potassium Channel Blocker 5-Hydroxydecanoate Inhibits Toxicity of 6-Hydroxydopamine on Dopaminergic Neurons
- 206 Downloads
The neurotoxin 6-hydroxydopamine is commonly used in models of Parkinson’s disease, and a potential factor in the pathogenesis of the disease. However, the mechanisms responsible for 6-hydroxydopamine-induced dopaminergic degeneration have not been totally clarified. Reactive oxygen species (ROS) derived from 6-OHDA uptake and intraneuronal autooxidation, extracellular 6-OHDA autooxidation, and microglial activation have been involved. The mitochondrial implication is controversial. Mitochondrial ATP-sensitive K (mitoK(ATP)) channels may provide a convergent target that could integrate these different mechanisms. We observed that in primary mesencephalic cultures and neuron-enriched cultures, treatment with the mitoK(ATP) channel blocker 5-hydroxydecanoate, inhibits the dopaminergic degeneration induced by low doses of 6-OHDA. Furthermore, 5-hydroxydecanoate blocks the 6-OHDA-induced decrease in mitochondrial inner membrane potential and inhibits 6-OHDA-induced generation of superoxide-derived ROS in dopaminergic neurons. The results suggest that low doses of 6-OHDA may generate low levels of ROS through several mechanisms, which may be insufficient to induce neuron death. However, they could act as a trigger to activate mitoK(ATP) channels, thereby enhancing ROS production and the subsequent dopaminergic degeneration. Furthermore, the present study provides additional data for considering mitoK(ATP) channels as a potential target for neuroprotection.
Keywords6-OHDA Mitok(ATP) channels Dopamine Parkinson’s disease Oxidative stress Mitochondria Neurodegeneration
This study was funded by Spanish Ministry of Education (MEC, BFU2006-07414/BFI), Spanish Ministry of Health (RD06/0010/0013 and Ciberned), and Galician Government (XUGA). The authors thank Pilar Aldrey for her excellent technical assistance.
- Irwin I, Langston JW (1995) Endogenous toxins as potential etiologic agents in Parkinson’s disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson’s disease. Marcel Dekker Inc.., New York, pp 153–201Google Scholar
- Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson’s disease. J Neural Transm 46:297–314Google Scholar
- Michel PP, Ruberg M, Agid G (1997) Rescue of mesencephalic dopamine neurons by anticancer drug cytosine arabinoside. J Neurochem 69:1459–1507Google Scholar
- Reinhardt R, Manaenko A, Guenther A, Franke H, Dickel T, Garcia de Arriba S, Muench G, Schneider D, Wagner A, Illes P (2003) Early biochemical and histological alterations in rat corticoencephalic cell cultures following metabolic damage and treatment with modulators of mitochondrial ATP-sensitive potassium channels. Neurochem Int 43:563–571PubMedCrossRefGoogle Scholar
- Soto-Otero R, Méndez-Álvarez E, Hermida-Ameijeiras A, Muñoz-Patiño A, Labandeira-García JL (2000) Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem 74:1605–1612PubMedCrossRefGoogle Scholar